comprehensive -WSS

comprehensive

author：hotspot 2025-09-14 14:46:31 - browse：9633

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Hearing on Medicare drug price negotiation gets unusually heated

focus

WSS

Hearing on Medicare drug price negotiation gets unusually heated

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Walmart eyes Medicare Advantage provider ChenMed

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Pig kidney works a record two months in donated body

IRA could hurt research into orphan drugs for rare diseases

hotspot

comprehensive

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Biotech lab space demand falls sharply

Wildfire smoke exposes gaps in outdoor worker protections

Acelyrin, a rare IPO success, stumbles in its first big test

Hepatitis C has a cure — but many Americans still lack access to it

FDA panel to weigh approval of NurOwn, controversial ALS drug

In age of alternative facts, a scholarly course on calling out crap

Readout LOUD podcast: possible new ALS drug, artificial wombs

Trump demands the U.S. pay no more for drugs than other countries … again

Intarcia’s device

hotspot

Readout LOUD podcast: possible new ALS drug, artificial wombs

White House touts steps to stem shortages of cancer treatments

What Congress can do to address the rural doctor shortage

Food makers to regulators: Ultra

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Changes to biosimilar regulatory framework must prioritize patients

leisure time

hotspot

focus

focus